# US 11,298,339 B2 · Bisdiazabicyclo compound for treatment and/or prevention of hepatitis virus-related diseases or disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,339 B2
- Document ID: US11298339B2
- Status: Granted
- Kind: B2
- Application number: 16/624,050
- Filed: 2018-11-20
- Published: 2021-09-23
- Granted: 2022-04-12
- Earliest claimed: 2017-11-24
- Assignees: Jiangsu Ascentage Biomed Development Inc.; Healthquest Pharma Inc.
- Applicants: Jiangsu Ascentage Biomed Development Inc.; Healthquest Pharma Inc.
- Inventors: Yifan Zhai; Xiaoyong Zhang; Jinlin Hou; Dajun Yang
- Web page: https://patentgrep.com/patent/US11298339B2

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.

## Claims

### Claim 1

A method of using a compound for treatment of a disease or disorder associated with a hepatitis virus, wherein the method comprises administering a therapeutically effective amount of the compound to a patient having the disease or disorder associated with a hepatitis virus, and the compound is a bisdiazabicyclo compound or a pharmaceutically acceptable salt thereof,
wherein the disease or disorder associated with hepatitis virus is hepatitis A, hepatitis B, hepatitis C, or liver cirrhosis, and
the compound is

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound is

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound treats the disease or disorder associated with hepatitis virus by modulating an immune response.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the method comprises using the compound in combination with a drug known to treat HBV.

### Claim 5

A method of treating a patient having hepatitis B, comprising administering to the patient a therapeutically effective amount of a compound, wherein the compound is
or a pharmaceutically acceptable salt thereof.